Vaxcyte Inc (PCVX) - Total Liabilities
Based on the latest financial reports, Vaxcyte Inc (PCVX) has total liabilities worth $352.29 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vaxcyte Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Vaxcyte Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Vaxcyte Inc to evaluate short-term liquidity relative to the company's equity base.
Vaxcyte Inc Competitors by Total Liabilities
The table below lists competitors of Vaxcyte Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yapi ve Kredi Bankasi AS
IS:YKBNK
|
Turkey | TL3.27 Trillion |
|
Ternium S.A
F:T5Z
|
Germany | €7.74 Billion |
|
AptarGroup Inc
NYSE:ATR
|
USA | $2.42 Billion |
|
NIBE INDUSTR. UNSP.ADR/1
F:NJB0
|
Germany | €34.77 Billion |
|
Korea Investment Holdings Co
KO:071050
|
Korea | ₩111.45 Trillion |
|
Planet Labs PBC
NYSE:PL
|
USA | $756.50 Million |
|
HUAYU Automotive Systems Co Ltd
SHG:600741
|
China | CN¥129.68 Billion |
|
Hangzhou Lion Electronics Co Ltd
SHG:605358
|
China | CN¥10.87 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Vaxcyte Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vaxcyte Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vaxcyte Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vaxcyte Inc (2017–2025)
The table below shows the annual total liabilities of Vaxcyte Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $360.45 Million | +75.40% |
| 2024-12-31 | $205.50 Million | +22.72% |
| 2023-12-31 | $167.45 Million | +218.56% |
| 2022-12-31 | $52.56 Million | +30.37% |
| 2021-12-31 | $40.32 Million | -14.18% |
| 2020-12-31 | $46.98 Million | -72.70% |
| 2019-12-31 | $172.07 Million | +33.88% |
| 2018-12-31 | $128.53 Million | +1378.55% |
| 2017-12-31 | $8.69 Million | -- |
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrie… Read more